<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284268</url>
  </required_header>
  <id_info>
    <org_study_id>FSJD-RTB-2015</org_study_id>
    <nct_id>NCT03284268</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma</brief_title>
  <acronym>RTB</acronym>
  <official_title>Phase I Study, Single Site, Open Label With Dose Escalation, for Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study, single site, open label with dose escalation, for evaluate safety and the
      oncolitic Adenovirus VCN-01 activity in patients with refractory retinoblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">November 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>180 days</time_frame>
    <description>The safety and tolerability of two intravitreal injections of VCN-01 will be determined with dose escalation until the maximum tolerated dose (MTD) is established based on the evaluation of adverse events and the observation of any dose-limiting toxicity (TLD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>28 days</time_frame>
    <description>Tumor response rate (ORR) to VCN-01 at 28 days post-administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VCN-01</measure>
    <time_frame>180 days</time_frame>
    <description>Virus presence in blood samples, aqueous humor, ocular surface and nasal swabs, and its difference between the viral particles before and after the treatment to evaluate the excretion profile of the CNV-01.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>180 days</time_frame>
    <description>The presence of neutralizing antibodies in blood samples in study patients to assess the immune response.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Histopathology of enucleated eyes after treatment with VCN-01</measure>
    <time_frame>180 days</time_frame>
    <description>Presence of VCN-01 in vitreous humor samples of enucleated eyes</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Retinoblastoma, Recurrent</condition>
  <arm_group>
    <arm_group_label>Dose escalation of VCN-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>VCN-01</intervention_name>
    <description>VCN-01 intravitreal injection</description>
    <arm_group_label>Dose escalation of VCN-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with retinoblastoma with either a somatic mutation of the geneRB1 with active
             tumor in a single eye, or with germinal mutation of RB1 with active tumor in a single
             eye and the contralateral eye unaffected or with active tumor in a single eye and the
             contralateral already enucleated eye relapsed or refractory with the use of systemic,
             intraarterial or intravitreal chemotherapy or radiotherapy in whom enucleation is the
             only recommended treatment.

          2. Normal renal function: serum creatinine: &lt;45μmol/L (0-2 years); &lt;57μmol/L (3-6 years);
             &lt;60μmol/L (7-10 years); &lt;80μmol/L (11-13 years).

          3. Normal Hepatic function: serum ALT: &lt;0,52μkat/L (de 9 months -12 years); serum AST:
             61-80 g/L (8 months - 5 years); 63-83 g/L (5-9 years); 63-82 g/L (9-12 years).

          4. Adequate marrow reserve manifested in an absolute neutrophil count&gt; 1000 / mm3,
             platelets&gt; 100,000 / mm3 and hemoglobin&gt; 8 g / dl, without transfusional or cytokine
             support at least one month prior to study entry.

          5. Age greater than one year and less than 12 years at the time of inclusion in the
             study.

          6. Informed consent form signed.

        Exclusion Criteria:

          1. Presence of factors that require immediate enucleation of the affected eye such as
             glaucoma, rubeosis iridis, anterior chamber involvement.

          2. Comorbidities: Uncontrolled epilepsy with anticonvulsant treatment, cardiac disease
             not compensated by treatment.

          3. Active Infections.

          4. Other chronic or active acute diseases that under the criterion of the researcher were
             an exclusion criterion.

          5. History of having received attenuated or live vaccines in the 30 days prior to
             inclusion in the study.

          6. Any cause of Immunosuppression.

          7. Trilateral Retinoblastoma.

          8. Extraocular spread.

          9. History of having received treatment for retinoblastoma with chemotherapy or radiation
             therapy by any means within 30 days prior to inclusion in the study.

         10. Patients who can not complete the study procedures for reasons psychological or
             social.

         11. Pregnancy. Female patients with procreative potential should be agree to undergo a
             blood or urine pregnancy test and the result should be negative to enter the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaume Catalá Mora, DR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan de Deu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaume Catalá Mora, Dr.</last_name>
    <phone>932 53 21 00</phone>
    <email>Jmora@sjdhospitalbarcelona.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillermo Chantada, Dr</last_name>
    <phone>932 53 21 00</phone>
    <email>gchantada@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Catalá Mora, Dr</last_name>
      <phone>932 53 21 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

